Dishman Pharma might take a lot of time in regaining investor confidence: Pankaj Pandey, ICICI Direct

Pankaj Pandey, Head Of Research, ICICI Direct, in a chat with ET Now talks about Dishman Pharma.

Have you analysed the financials of Dishman Pharma?

Dishman Pharma is in our coverage. We had a prior reduced rating on that stock. For the past five or six quarters, the management has not been able to deliver in terms of what they have been setting expectations. So this time around, people have really given up hope on the stock.

Going forward, the stock might take a lot of time in terms of regaining the investor confidence. So that is a case with a stock like Dishman Pharma.